Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HPGD | P15428 | 5/20 | 0.63 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.63 |
| ▸ | MAPT | P10636 | 2/20 | 0.63 |
| ▸ | MLYCD | O95822 | 1/20 | 0.61 |
| ▸ | HSP90AA1 | P07900 | 5/20 | 0.59 |
| ▸ | HSP90AB1 | P08238 | 5/20 | 0.59 |
| ▸ | OPRM1 | P35372 | 2/20 | 0.59 |
| ▸ | OPRD1 | P41143 | 2/20 | 0.59 |
| ▸ | LMNA | P02545 | 2/20 | 0.56 |
| ▸ | MEN1 | O00255 | 1/20 | 0.56 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.56 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.56 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.56 |
| ▸ | RAB9A | P51151 | 2/20 | 0.56 |
| ▸ | NPC1 | O15118 | 1/20 | 0.56 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.54 |
| ▸ | BLM | P54132 | 1/20 | 0.54 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5703500 | 0.91 | HPGD (0.73) | HPGDALDH1A1MAPTMLYCDHSP90AA1 | |
| SCHEMBL13236606 | 0.85 | HPGD (0.49) | HPGDALDH1A1MAPTMLYCDHSP90AA1 | |
| SCHEMBL4489409 | 0.83 | MLYCD (0.64) | HPGDALDH1A1MLYCDTDP1 | |
| SCHEMBL6802252 | 0.83 | HPGD (0.69) | HPGDALDH1A1MAPTMLYCDHSP90AA1 | |
| SCHEMBL121475 | 0.83 | HPGD (0.66) | HPGDALDH1A1MAPTMLYCDHSP90AA1 | |
| SCHEMBL26015713 | 0.82 | HPGD (0.61) | HPGDALDH1A1LMNA | |
| SCHEMBL24629175 | 0.81 | HPGD (0.57) | HPGDALDH1A1MAPTMLYCDHSP90AA1 | |
| SCHEMBL1018549 | 0.81 | HPGD (0.61) | HPGDALDH1A1MAPTMLYCDHSP90AA1 | |
| SCHEMBL471629 | 0.81 | HPGD (0.61) | HPGDALDH1A1MAPTMLYCDHSP90AA1 | |
| SCHEMBL3081053 | 0.81 | HPGD (0.61) | HPGDALDH1A1MAPTMLYCDHSP90AA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 57 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-115473001-B | Battery separator, preparation method thereof and battery | 江苏中兴派能电池有限公司 | 2023-08-29 | — | — | CN | claimed |
| CN-115473001-A | Battery diaphragm, preparation method thereof and battery | 江苏中兴派能电池有限公司 | 2022-12-13 | — | — | CN | claimed |
| CN-1294519-A | Pharmaceutical composition containing a compound having an activity of promoting the absorption of an active ingredient | INPHARMA SA (CH) | 2001-05-09 | — | — | CN | claimed |
| EP-4630813-A2 | IMPROVED METHOD FOR SCALABLE UNTARGETED METABOLOMIC WORKFLOW | Washington University (US) | 2025-10-15 | — | — | EP | disclosed |
| WO-2024123681-A2 | IMPROVED METHOD FOR SCALABLE UNTARGETED METABOLOMIC WORKFLOW | WASHINGTON UNIVERSITY (US) | 2024-06-13 | — | — | WO | disclosed |
| CN-115473001-B | Battery separator, preparation method thereof and battery | 江苏中兴派能电池有限公司 | 2023-08-29 | — | — | CN | disclosed |
| US-11735772-B2 | Electrolytes for electrochemical energy storage | UCHICAGO ARGONNE, LLC (US) | 2023-08-22 | — | — | US | disclosed |
| CN-115473001-A | Battery diaphragm, preparation method thereof and battery | 江苏中兴派能电池有限公司 | 2022-12-13 | — | — | CN | disclosed |
| EP-2493863-B1 | PHENOXY-SUBSTITUTED PYRIMIDINES AS OPIOID RECEPTOR MODULATORS | JANSSEN PHARMACEUTICA NV (BE) | 2015-02-25 | — | — | EP | disclosed |
| EP-2493863-B1 | PHENOXY-SUBSTITUTED PYRIMIDINES AS OPIOID RECEPTOR MODULATORS | JANSSEN PHARMACEUTICA NV (BE) | 2015-02-25 | — | — | EP | disclosed |
| CN-102686569-B | Phenoxy substituted pyrimidines as opioid receptor modulators | JANSSEN PHARMACEUTICA NV | 2014-11-26 | — | — | CN | disclosed |
| WO-2005089747-A1 | NOVEL AZABICYCLIC DERIVATIVES, PREPARATION METHOD THEREOF AND PHARMACEUTICAL COMPOSITIONS CONTAINING SAME | LES LABORATOIRES SERVIER (FR) | 2005-09-29 | — | — | WO | disclosed |
| CN-1178699-C | Pharmaceutical Compsns. contg. compounds with activity for enhancement of absorption of active ingredients | — | 2004-12-08 | — | — | CN | disclosed |
| CN-1294519-A | Pharmaceutical composition containing a compound having an activity of promoting the absorption of an active ingredient | INPHARMA SA (CH) | 2001-05-09 | — | — | CN | disclosed |
| US-5866611-A | PHENOXYPROPYLAMINE INHIBITORS OF SQUALENE SYNTHESE, USEFUL IN TREATING DISEASES IN WHICH A LOWERING OF CHOLESTEROL IS DESIRABLE. | ZENECA LIMITED (GB) | 1999-02-02 | — | — | US | disclosed |
| EP-0589018-A1 | AMINES AS INHIBITORS OF SQUALENE SYNTHASE | ZENECA LIMITED (GB) | 1994-03-30 | — | — | EP | disclosed |
| EP-0393513-B1 | Preparation of a difluorohalomethoxybenzene | MITSUI TOATSU CHEMICALS (JP) | 1994-03-09 | — | — | EP | disclosed |
| WO-1993020807-A1 | AMINES AS INHIBITORS OF SQUALENE SYNTHASE | ZENECA LIMITED (GB) | 1993-10-28 | — | — | WO | disclosed |
| US-5105021-A | Reacting metal phenolate with (di)bromo(chloro)difluoromethane in presence of promoter | MITSUI TOATSU CHEMICALS, INCORPORATED (JP) | 1992-04-14 | — | — | US | disclosed |
| EP-0393513-A1 | Preparation of a difluorohalomethoxybenzene | MITSUI TOATSU CHEMICALS, Inc. (JP) | 1990-10-24 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11735772-B2 | Electrolytes for electrochemical energy storage | HCN2, SLC9A2, HCN3 | HPGD 26/4885ALDH1A1 433/4885MAPT 2581/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.